Lexpos News

Today the Government announced that regulations restricting the prescribing and supply of puberty-suppressing hormones – which were due to expire at the end of December –will be made indefinite. The Medicines (Gonadotrophin-Releasing Hormone Analogues) (Restrictions on Private Sales and Supplies) Order 2024 will come into force on 1 January 2025 as the current emergency order expires and [...]

The post Legislation restricting the sale and supply of gonadotrophin-releasing hormone analogues will be made indefinite appeared first on Community Pharmacy England.

The Managing Director of Jardines (UK) Ltd and Superintendent Pharmacist of Pearl Chemist Group have been selected as non-CCA multiple observers to the Community Pharmacy England Committee. The establishment of two contributing observer places is an interim measure to ensure pharmacy owners with 10 or more pharmacies are well represented, while the Committee considers more [...]

The post Additional non-CCA multiples appointed to Community Pharmacy England Committee appeared first on Community Pharmacy England.

In response to a significant ongoing disruption to the supply of Cefalexin 125mg/5ml oral suspension sugar free and Cefalexin 250mg/5ml oral suspension sugar free, two Serious Shortage Protocol (SSP) has been issued by the Department of Health and Social Care (DHSC). Effective today 10 December 2024, SSP077 provides that for every 5 ml of Cefalexin 125mg/5ml [...]

The post Two SSPs issued for Cefalexin oral suspension sugar free appeared first on Community Pharmacy England.

NHS England and Community Pharmacy England recommend that pharmacy team members with NHS Smartcards consider taking the following actions to support ongoing use of their smartcards. If your smartcard or role on your smartcard was set up a long time ago, there may be an action for you to update it to keep it working. [...]

The post NHS Smartcard action required: checking contact info, self unlock and expiry appeared first on Community Pharmacy England.

Drug alert number: EL (24)A/62 Date issued: 9 December 2024 Wockhardt UK Limited is recalling this batch as a precautionary measure following the identification of a low number of units which may have a defect in the ‘top case’ resulting in a dose not being able to be dispensed. WockAIR 160 microgram/4.5 microgram, inhalation powder, [...]

The post MHRA Class 2 Medicines Recall: WockAIR 160 microgram/4.5 microgram, inhalation powder (Wockhardt UK Limited) appeared first on Community Pharmacy England.